Aankondiging • Jun 25
MaxCyte Shareholders Approves Common Stock Cancelation Date MaxCyte, Inc. provided further update with regards to the cancellation of admission of the Company's common stock ("Common Stock") to trading on AIM (the "Cancellation"), as approved by shareholders at the Annual General Meeting held on 18 June 2025. Shareholders are reminded that the last day of dealings in the Company's Common Stock on AIM will be 25 June 2025 and that the cancellation of their admission to trading on AIM will take place at 7:00 a.m. (UK time) on 26 June 2025. Following the delisting, there will be no public market in the United Kingdom on which the Common Stock can be traded, however the Company will retain its U.S. listing of Common Stock on the Nasdaq Global Select Market ("Nasdaq") under ticker symbol MXCT. Aankondiging • May 08
MaxCyte, Inc. Reiterates Revenue Guidance for the Year 2025 MaxCyte, Inc. reiterated revenue guidance for the year 2025. For the year, the company reiterates core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments. Aankondiging • Apr 17
MaxCyte, Inc., Annual General Meeting, Jun 18, 2025 MaxCyte, Inc., Annual General Meeting, Jun 18, 2025. Location: 9713 key west avenue, suite 400, rockville, 20850, maryland United States Aankondiging • Apr 10
MaxCyte, Inc. to Report Q1, 2025 Results on May 07, 2025 MaxCyte, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025 Reported Earnings • Mar 12
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: US$0.39 loss per share (further deteriorated from US$0.37 loss in FY 2023). Revenue: US$38.6m (down 6.4% from FY 2023). Net loss: US$41.1m (loss widened 8.3% from FY 2023). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 6.1%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Aankondiging • Mar 12
MaxCyte, Inc. Provides Revenue Guidance for the Year 2025 MaxCyte, Inc. provided revenue guidance for the year 2025. For the period, the company expects core revenue is expected to grow 8% to 15% compared to 2024, inclusive of revenue from SeQure Dx. SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments. Aankondiging • Feb 07
MaxCyte, Inc. to Report Q4, 2024 Results on Mar 11, 2025 MaxCyte, Inc. announced that they will report Q4, 2024 results at 4:30 PM, GMT Standard Time on Mar 11, 2025 Aankondiging • Jan 30
MaxCyte, Inc. (AIM:MXCT) acquired SeQure Dx, Inc. for $7 million. MaxCyte, Inc. (AIM:MXCT) acquired SeQure Dx, Inc. for $7 million on January 30, 2025. Maxcyte paid a total consideration of $4.5 million at closing in cash for the entire issued share capital of SeQure DX on a cash free, debt free basis using Maxcyte’s existing cash resources and an additional amount of $2.5 million to be paid in contingent consideration if the SeQure exceeds certain revenue targets. For the period ending December 31, 2024, SeQure Dx, Inc. reported total revenue of $1.7 million and net loss of $6.5 million and total assets of $0.7 million.
MaxCyte, Inc. (AIM:MXCT) completed the acquisition of SeQure Dx, Inc. on January 30, 2025. Buy Or Sell Opportunity • Jan 24
Now 24% undervalued Over the last 90 days, the stock has risen 31% to UK£3.82. The fair value is estimated to be UK£5.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.9% over the last 3 years. Earnings per share has declined by 24%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 15% in the next 2 years. New Risk • Jan 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$30m net loss in 2 years). Share price has been volatile over the past 3 months (7.2% average weekly change). Aankondiging • Dec 23
MaxCyte, Inc. Announces Retirement of Board Member Art Mandell MaxCyte, Inc. announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxCyte’s growth and strategic direction. Upon Mr. Mandell’s retirement, MaxCyte will have nine directors. During Mr. Mandell’s tenure, MaxCyte has achieved significant milestones including its initial public offering on the UK AIM exchange and US Nasdaq Listing, the launch of its flagship ExPERT™ platform, signing 29 Strategic Platform Licenses with cell and gene therapy biotech companies and supporting the industry’s first, FDA-approved, CRISPR edited non-viral cell therapy. Aankondiging • Dec 10
MaxCyte, Inc. Raises Revenue Guidance for 2024 MaxCyte, Inc. raised Revenue guidance for 2024. For the period, the company expects core business revenue of 6% to 8% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY. Reported Earnings • Nov 07
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: US$0.11 loss per share (further deteriorated from US$0.11 loss in 3Q 2023). Revenue: US$8.16m (up 2.0% from 3Q 2023). Net loss: US$11.6m (loss widened 2.7% from 3Q 2023). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings. Aankondiging • Nov 07
MaxCyte, Inc. Updates Revenue Guidance for the Full Year 2024 MaxCyte, Inc. updated revenue guidance for the full year 2024. For the period, Company expects core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY. Aankondiging • Oct 15
MaxCyte, Inc. Announces Appointment of Cynthia Collins as Non-Executive Director MaxCyte, Inc. announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. Ms. Collins brings over 40 years of experience in the biotechnology industry and cell and gene medicines to MaxCyte, including her most recent role as Chief Executive Officer of Editas Medicine, where she was involved in dosing the first patient ever with an in-vivo gene modified therapy. Previously, Ms. Collins served as Chief Executive Officer of Human Longevity Inc., Chief Executive Officer/General Manager of General Electric Healthcare's Cell Therapy and Lab Businesses, and Chief Executive Officer of GenVec, Inc., a vaccine and gene therapy company. Currently, Ms. Collins serves as a member of the Board of Directors of several healthcare companies, including Alanis Therapeutics, Nutcracker Therapeutics, Poseida Therapeutics, Certara, DermTech, Draper Laboratory, and Panavance Therapeutics. She is also a board member of the Foundation for mRNA Medicines. Cynthia Collins holds a Bachelor of Science degree in Microbiology from the University of Illinois, Urbana and an MBA from The University of Chicago Booth School of Business. Cynthia Collins, was previously appointed as an independent director to the Board of DermTech, Inc. on May 24, 2018. On June 18, 2024, the Company filed for Chapter 11 bankruptcy. On August 21, 2024 the US Bankruptcy Court for the District of Delaware approved the sale of a substantial amount of DermTech Inc.'s assets through a court-supervised auction. Aankondiging • Oct 11
MaxCyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024 MaxCyte, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024 Aankondiging • Oct 10
MaxCyte, Inc. Appoints Ali Soleymannezhad as Chief Commercial Officer MaxCyte, Inc. announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte’s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company’s market impact in Cell and Gene Therapy. Prior to his role as Chief Commercial Officer, Mr. Soleymannezhad was the Executive Vice President of Bioprocessing, where he led global product development and marketing strategy for MaxCyte’s bioprocessing business. Mr. Soleymannezhad brings 20 years of technical sales, marketing, and product development experience to his new role. Prior to Executive Vice President of Bioprocessing at MaxCyte, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience and oversaw a team of 140 employees across four global manufacturing, development, and commercial sites. Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing-Americas at Tosoh and served on the board of Semba Biosciences. Recent Insider Transactions Derivative • Oct 04
Independent Non-Executive Director exercised options and sold UK£133k worth of stock On the 2nd of October, Stanley Erck exercised 48k options at a strike price of around UK£0.03 and sold these shares for an average price of UK£2.83 per share. This trade did not impact their existing holding. Since June 2024, Stanley has owned 247.75k shares directly. Company insiders have collectively sold UK£760k more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Sep 05
Independent Non-Executive Director notifies of intention to sell stock Stanley Erck intends to sell 143k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of September. If the sale is conducted around the recent share price of UK£3.30, it would amount to UK£472k. Since June 2024, Stanley has owned 247.75k shares directly. Company insiders have collectively sold UK£481k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Aug 07
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Second quarter 2024 results: US$0.09 loss per share (improved from US$0.10 loss in 2Q 2023). Revenue: US$10.4m (up 15% from 2Q 2023). Net loss: US$9.38m (loss narrowed 11% from 2Q 2023). Revenue exceeded analyst estimates by 31%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings. Aankondiging • Aug 07
MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024 MaxCyte, Inc. reaffirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and increases SPL Program-related revenue guidance. The company continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM. Aankondiging • Jul 10
MaxCyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024 MaxCyte, Inc. announced that they will report Q2, 2024 results at 4:30 PM, GMT Standard Time on Aug 06, 2024 Aankondiging • Jul 03
MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth Index MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth Index Recent Insider Transactions Derivative • Jun 23
Insider notifies of intention to sell stock Thomas Ross intends to sell 133k shares in the next 90 days after lodging an Intent To Sell Form on the 20th of June. If the sale is conducted around the recent share price of UK£3.48, it would amount to UK£464k. As of today, Thomas currently holds no shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively sold UK£447k more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Jun 13
President recently bought UK£384k worth of stock On the 10th of June, Maher Masoud bought around 100k shares on-market at roughly UK£3.84 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Maher's only on-market trade for the last 12 months. New Risk • May 09
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.07% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 0.07% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$41m net loss in 2 years). Aankondiging • May 09
Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024 MaxCyte, Inc. affirmed revenue guidance for the full year 2024. The company affirmed 2024 revenue guidance for core business revenue and is increasing SPL Program-related revenue guidance. MaxCyte continues to expect full year 2024 core business revenue to be flat to 5% growth compared to 2023. SPL Program-related revenue is now expected to be approximately $5 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVY™. Reported Earnings • May 08
First quarter 2024 earnings: EPS and revenues exceed analyst expectations First quarter 2024 results: US$0.092 loss per share (improved from US$0.11 loss in 1Q 2023). Revenue: US$11.3m (up 32% from 1Q 2023). Net loss: US$9.53m (loss narrowed 13% from 1Q 2023). Revenue exceeded analyst estimates by 51%. Earnings per share (EPS) also surpassed analyst estimates by 28%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings. Aankondiging • Apr 28
MaxCyte, Inc., Annual General Meeting, Jun 11, 2024 MaxCyte, Inc., Annual General Meeting, Jun 11, 2024, at 11:00 US Eastern Standard Time. Location: 9713 Key West Avenue, Suite 400 Rockville Maryland United States Agenda: To elect the Board’s three nominees as identified in the accompanying Proxy Statement as Class III directors: Will Brooke, John Johnston, and Richard Douglas; to approve an amendment to the MaxCyte, Inc. 2022 Equity Incentive Plan to increase the shares of the Company’s common stock issuable thereunder by 2,300,000 shares; to ratify the Audit Committee’s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; and to conduct any other business properly brought before the meeting. Aankondiging • Apr 11
MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024 MaxCyte, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024 Major Estimate Revision • Mar 19
Consensus revenue estimates fall by 13% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$39.5m to US$34.5m. Forecast losses increased from -US$0.43 to -US$0.483 per share. Life Sciences industry in the United Kingdom expected to see average net income decline 35% next year. Consensus price target broadly unchanged at UK£7.64. Share price rose 4.0% to UK£3.28 over the past week. Aankondiging • Mar 14
MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024 MaxCyte, Inc. reiterated earnings guidance for the year 2024. Management is reiterating 2024 revenue guidance for core business revenue and SPL Program-related revenue. Management expects full year 2024 core business revenue to be flat to 5% growth compared to 2023, and SPL Program-related revenue is expected to be approximately $3 million. Outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR’s CASGEVYTM and reflects a difficult year-over-year comparison from a client milestone recognized in 2023 that was initially expected in 2024. Reported Earnings • Mar 13
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: US$0.37 loss per share (further deteriorated from US$0.23 loss in FY 2022). Revenue: US$41.3m (down 6.7% from FY 2022). Net loss: US$37.9m (loss widened 61% from FY 2022). Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.5%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 25% per year whereas the company’s share price has fallen by 30% per year. Aankondiging • Mar 07
MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024 MaxCyte, Inc. provided revenue guidance for the fiscal year 2023 and 2024. For the year 2023, Company re-affirms total revenue to be between $41.1 million and $41.3 million, compared to $44.3 million for fiscal year 2022. Core revenue is expected to be between $29.6 million and $29.8 million, compared to $39.6 million for fiscal year 2022.For the Year 2024, Company expects Core revenue to be flat to 5% growth compared to 2023. Aankondiging • Feb 10
MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024 MaxCyte, Inc. announced that they will report fiscal year 2023 results After-Market on Mar 12, 2024 Aankondiging • Jan 27
MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer MaxCyte, Inc. announced on January 23, 2024, Cenk Sumen, Ph.D.’s employment as chief scientific officer of the company ended. Dr. Sumen will maintain a relationship with the Company as a member of the company’s Scientific Advisory Board. Aankondiging • Jan 09
MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 MaxCyte, Inc. provided preliminary financial guidance for the fourth quarter and full year ended December 31, 2023. Total revenue for the fourth quarter of 2023 is expected to be between $15.5 million and $15.7 million, compared to $12.4 million in the fourth quarter of 2022.Total revenue for the fiscal year of 2023 is expected to be between $41.1 and $41.3 million, compared to $44.3 million for fiscal year 2022. Aankondiging • Dec 12
MaxCyte, Inc. Provides Revenue Guidance Update for 2023 MaxCyte, Inc. is reiterating 2023 expected core business revenue of $28 million- $30 million, and the company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million. Core business revenue consists of sales and leases of instrument and disposables to cell therapy and drug discovery customers and excludes any milestone revenues under SPL programs. Recent Insider Transactions Derivative • Dec 03
Founder exercised options and sold UK£100k worth of stock On the 1st of December, Douglas Doerfler exercised 26k options at a strike price of around UK£0.032 and sold these shares for an average price of UK£3.94 per share. This trade did not impact their existing holding. For the year to December 2016, Douglas' total compensation was 38% salary and 62% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£1.6m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Nov 18
Independent Non-Executive Director notifies of intention to sell stock John Johnston intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 14th of November. If the sale is conducted around the recent share price of UK£2.97, it would amount to UK£59k. Since March 2023, John has owned 120.58k shares directly. Company insiders have collectively sold UK£1.4m more than they bought, via options and on-market transactions in the last 12 months. New Risk • Nov 10
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$42m net loss in 2 years). Share price has been volatile over the past 3 months (7.9% average weekly change). Aankondiging • Nov 10
MaxCyte, Inc. Provides Revenue Guidance for the Year 2023 MaxCyte, Inc. provided revenue guidance for the year 2023. For the period, the company expects total revenue to be approximately $34 million - 36 million. Reported Earnings • Nov 09
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.063 loss in 3Q 2022). Revenue: US$8.00m (down 25% from 3Q 2022). Net loss: US$11.3m (loss widened 75% from 3Q 2022). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 7.8%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. New Risk • Nov 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$36m net loss in 2 years). Share price has been volatile over the past 3 months (7.5% average weekly change). Aankondiging • Oct 07
MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023 MaxCyte, Inc. provided revenue guidance for the third quarter and full year of 2023. Total revenue of $7.8 million to $8.0 million in the third quarter of 2023, a decrease of 25% to 27% compared to the third quarter of 2022; the decline is due to continued reduced customer activity in the sector.For the full year, the company’s total revenue now expected to be approximately $34 million to $36 million. Major Estimate Revision • Oct 06
Consensus revenue estimates fall by 22% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$45.0m to US$34.9m. Forecast losses increased from -US$0.348 to -US$0.358 per share. Life Sciences industry in the United Kingdom expected to see average net income decline 0.1% next year. Consensus price target down from UK£7.68 to UK£6.88. Share price fell 18% to UK£2.10 over the past week. Aankondiging • Oct 05
MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023 MaxCyte, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023 Aankondiging • Sep 07
Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing MaxCyte, Inc. announced the appointment of Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21, 2023. Mr. Soleymannezhad will lead global product development and marketing strategy for MaxCyte's bioprocessing business. The bioprocessing business is anchored by the STx and VLx platforms supporting biotherapeutic research, development and manufacturing using transient expression to produce complex proteins, vaccines and biologics at scale. Mr. Soleymannezhad brings almost 20 years of technical, sales and marketing expertise in biomanufacturing, bioprocessing and bioanalysis to his new role. Most recently, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience overseeing a team of 140 employees across four global manufacturing, development, and commercial sites. During his tenure at Tosoh, Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing Americas and served on the board of Semba Biosciences. Mr. Soleymannezhad received a Master of Business Administration in finance from Jones Graduate School of Business at Rice University in Texas after completing his Master and Bachelor of Chemical Engineering at University of Western Ontario's Faculty of Engineering in Canada. New Risk • Aug 13
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.1% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$36m net loss in 2 years). Reported Earnings • Aug 10
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: US$0.10 loss per share (further deteriorated from US$0.081 loss in 2Q 2022). Revenue: US$9.04m (down 5.9% from 2Q 2022). Net loss: US$10.5m (loss widened 27% from 2Q 2022). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 4.2%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Aankondiging • Aug 10
MaxCyte, Inc. Provides Revenue Guidance for the Year 2023 MaxCyte, Inc. provided revenue guidance for the year 2023. For the year, the company expects core revenue to be comparable to 2022 and Strategic Platform License program-related revenue expectations remain unchanged at approximately $6 million. Aankondiging • Jul 14
MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023 MaxCyte, Inc. announced that they will report Q2, 2023 results at 4:30 PM, GMT Standard Time on Aug 09, 2023 Recent Insider Transactions Derivative • Jul 13
Founder notifies of intention to sell stock Douglas Doerfler intends to sell 90k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of July. If the sale is conducted around the recent share price of UK£3.61, it would amount to UK£325k. For the year to December 2016, Douglas' total compensation was 38% salary and 62% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£1.6m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Jun 29
Independent Non-Executive Director notifies of intention to sell stock John Johnston intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 26th of June. If the sale is conducted around the recent share price of UK£3.68, it would amount to UK£92k. Since March 2023, John has owned 120.58k shares directly. Company insiders have collectively sold UK£1.6m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Jun 17
Founder exercised options and sold UK£173k worth of stock On the 14th of June, Douglas Doerfler exercised 44k options at a strike price of around UK£0.032 and sold these shares for an average price of UK£3.97 per share. This trade did not impact their existing holding. For the year to December 2016, Douglas' total compensation was 38% salary and 62% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£1.6m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • May 17
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$54.2m to US$48.3m. Forecast losses increased from -US$0.322 to -US$0.33 per share. Life Sciences industry in the United Kingdom expected to see average net income growth of 1.6% next year. Consensus price target down from UK£9.67 to UK£8.52. Share price fell 20% to UK£3.05 over the past week. Reported Earnings • May 11
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.04 loss in 1Q 2022). Revenue: US$8.58m (down 26% from 1Q 2022). Net loss: US$10.9m (loss widened 168% from 1Q 2022). Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) also surpassed analyst estimates by 1.8%. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Aankondiging • May 11
MaxCyte, Inc. Provides Revenue Guidance for the Year 2023 MaxCyte, Inc. provided revenue guidance for the year 2023. For the year, the company expects total revenue to grow between 8% and 12% compared to 2022, with core revenue growth of 5% to 10% and Strategic Platform License (“SPL”) program-related revenue expectations remaining the same at approximately $6 million for the year. Board Change • Apr 02
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Member of Scientific Advisory Board Marcela Maus was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Apr 01
Key Executive recently bought UK£280k worth of stock On the 29th of March, Richard Douglas bought around 80k shares on-market at roughly UK£3.51 per share. This transaction increased Richard's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months. Reported Earnings • Mar 16
Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021) Full year 2022 results: US$0.23 loss per share (further deteriorated from US$0.21 loss in FY 2021). Revenue: US$44.3m (up 31% from FY 2021). Net loss: US$23.6m (loss widened 24% from FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 43% per year, which means it is well ahead of earnings. Recent Insider Transactions Derivative • Feb 05
Founder exercised options and sold UK£139k worth of stock On the 2nd of February, Douglas Doerfler exercised 30k options at a strike price of around UK£0.033 and sold these shares for an average price of UK£4.66 per share. This trade did not impact their existing holding. For the year to December 2016, Douglas' total compensation was 28% salary and 72% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£996k more than they bought, via options and on-market transactions in the last 12 months. Aankondiging • Feb 02
MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023 MaxCyte, Inc. announced that they will report Q4, 2022 results at 4:30 PM, GMT Standard Time on Mar 15, 2023 Recent Insider Transactions Derivative • Jan 07
Founder exercised options and sold UK£127k worth of stock On the 5th of January, Douglas Doerfler exercised 30k options at a strike price of around UK£0.034 and sold these shares for an average price of UK£4.27 per share. This trade did not impact their existing holding. For the year to December 2016, Douglas' total compensation was 28% salary and 72% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Douglas has owned 333.20k shares directly. Company insiders have collectively sold UK£642k more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Dec 07
Insider exercised options and sold UK£113k worth of stock On the 5th of December, Thomas Ross exercised 29k options at a strike price of around UK£0.89 and sold these shares for an average price of UK£4.77 per share. This trade did not impact their existing holding. As of today, Thomas currently holds no shares directly. Company insiders have collectively sold UK£415k more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Nov 16
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -US$0.29 to -US$0.26 per share. Revenue forecast steady at US$44.7m. Life Sciences industry in the United Kingdom expected to see average net income growth of 24% next year. Consensus price target broadly unchanged at UK£10.12. Share price rose 3.5% to UK£5.85 over the past week. Recent Insider Transactions Derivative • Nov 04
Insider exercised options and sold UK£154k worth of stock On the 2nd of November, Thomas Ross exercised 29k options at a strike price of around UK£0.73 and sold these shares for an average price of UK£6.03 per share. This trade did not impact their existing holding. As of today, Thomas currently holds no shares directly. Company insiders have collectively sold UK£6.8m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Oct 13
Insider exercised options and sold UK£147k worth of stock On the 11th of October, Thomas Ross exercised 29k options at a strike price of around UK£0.76 and sold these shares for an average price of UK£5.81 per share. This trade did not impact their existing holding. As of today, Thomas currently holds no shares directly. Company insiders have collectively sold UK£6.6m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • Aug 17
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$43.6m to US$44.7m. Forecast EPS reduced from -US$0.25 to -US$0.28 per share. Life Sciences industry in the United Kingdom expected to see average net income growth of 24% next year. Consensus price target up from UK£9.76 to UK£10.18. Share price rose 6.2% to UK£4.73 over the past week. Reported Earnings • Aug 11
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Second quarter 2022 results: US$0.081 loss per share (down from US$0.052 loss in 2Q 2021). Revenue: US$9.61m (up 35% from 2Q 2021). Net loss: US$8.26m (loss widened 87% from 2Q 2021). Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 21%, compared to a 25% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 10
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: US$0.04 loss per share (up from US$0.088 loss in 1Q 2021). Revenue: US$11.6m (up 78% from 1Q 2021). Net loss: US$4.07m (loss narrowed 43% from 1Q 2021). Revenue exceeded analyst estimates by 36%. Earnings per share (EPS) also surpassed analyst estimates by 43%. Over the next year, revenue is forecast to grow 17%, compared to a 17% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. 
